CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 204 enrolled
Drug / intervention
Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00735449
NCT00735449Phase 4Completed
CompareCT.gov

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

Allergan·interventional·Posted Aug 15, 2008·Updated Apr 23, 2019

In Brief

A Phase 4 clinical trial evaluating Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, and 1 other intervention for Glaucoma and Ocular Hypertension. Completed, enrolled 204 participants across 2 sites in 2 countries.

Detailed Summary

Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2008
Enrollment StartJul 1, 2008
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.9 years ago

Interventions

Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%drug

1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.

timolol maleate 0.5%drug

1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.

latanoprost 0.005%drug

1 drop of latanoprost 0.005% once nightly.